Despite a lot of turbulence in both the headlines and the markets, growth stocks are on pace to deliver yet another strong year, just like Wall Street expected.
A quick recap: Equities were hobbled early in 2026 by numerous concerns, including fading economic growth, new tariff policies, and another government shutdown. That was all before America's war with Iran, which sent the major indexes near or into correction territory. Even the typically growth-happy tech sector struggled as artificial intelligence (AI) advancements raised fears that the rapidly evolving technology could displace numerous software makers and other IT industries.
However, Wall Street's pros remained unbowed, keeping their optimistic ratings in place across the sector. And they weren't wrong: A little froth off the top made these growth stocks look more attractive from a valuation standpoint, and investors have spent the past few months buying back in and sending the major indexes to new highs.
What comes next?
Let's look at a few of the best growth stocks for the rest of 2026 and beyond. These are companies that Wall Street's analyst community believes will rapidly grow their top and bottom lines in the years to come—and whose stocks they expect will be propelled higher as a result.
Disclaimer: This article does not constitute individualized investment advice. Individual securities, funds, and/or other investments appear for your consideration and not as personalized investment recommendations. Act at your own discretion.
The Best Growth Stocks to Buy Now
The top growth stocks right now are companies expanding faster than the broader market, as well as their peers. That often involves riding a long-term trend that will result in a durable tailwind for years to come.
Nothing is certain on Wall Street, of course, and growth stocks that showed strong revenue trends or stock price appreciation over the past year might still stumble if things change in the months to come. That said, investors who pay attention to growth stock data can often identify companies moving into favor—and share in their success.
Today, I'll look at some of the best growth stocks to buy now based on recent performance, financial metrics, and equity analysts' ratings and growth projections. I'll include both long-term earnings-growth estimates and consensus analyst ratings, courtesy of S&P Global Market Intelligence. The consensus rating is the average of all known analyst ratings of the stock, boiled down to a numerical system where ...
- 1-1.5 = Strong Buy
- 1.5-2.5 = Buy
- 2.5-3.5 = Hold
- 3.5-4.5 = Sell
- 4.5-5 = Strong Sell
In short, the lower the number, the better the overall consensus view on the stock.
All stocks here are rated at least 2.0 or below, meaning at worst they're solidly in the Buy camp, though most of the picks are considered Strong Buys as we near the end of 2026.
Do you want to get serious about saving and planning for retirement? Sign up for Retire With Riley, Young and the Invested's free retirement planning newsletter.
Neurocrine Biosciences
- Sector: Healthcare
- Market cap: $14.6 billion
- Long-term earnings growth estimate: 41%
- Consensus analyst rating: 1.41 (Strong Buy)
Any list of the best growth stocks is bound to include the occasional pharmaceutical or biotechnology name. And that's the case here, with Neurocrine Biosciences (NBIX) leading off our list of Wall Street's most favored growth investments.
Neurocrine discovers and develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders. Its commercial products include Ingrezza (tardive dyskinesia and chorea associated with Huntington's disease), Alkindi (adrenal insufficiency), Orilissa (endometriosis), and Efmody and Crenessity (classic congenital adrenal hyperplasia, or CAH). The last drug there is a relative newbie to the lineup, earning FDA approval in late 2024. But it is fast becoming a major contributor to Neurocrine's top line, and it helped the company beat expectations in its most recent earnings report.
Related: 13 Best Stock Screeners + Stock Scanners [Apps & Sites]
"The [second-quarter] report reflected strength across multiple products with a total revenue beat of ~$67M, driven by Ingrezza and Crenessity," Wedbush analysts Laura Chico and Thomas Yip (Outperform, equivalent of Buy) said following the company's most recent earnings announcement. "Crenessity and a partial quarter of Vykat XR revenue combined for more than $200 million and represents meaningful diversification beyond Ingrezza."
"Psychiatry opportunities appear well-positioned for commercialization," add Oppenheimer analysts, who also have NBIX at Outperform. "We asked about the potential launches for osavampator and direclidine, and management emphasized that existing infrastructure provides a strong foundation while [phase 3 trial] readouts remain on track for 2027. We see an underappreciated advantage for NBIX to leverage commercial scale, and believe osavampator could eventually benefit from [primary care physician] expansion."
The broader analyst community is plenty rosy on Neurocrine Biosciences shares—currently, 25 pros rate shares a Buy, versus four Holds and zero Sells. They see the company growing its top line by about 30% annually through the end of 2027, and the bottom line by around 40% annually across the next three to five years.
The current consensus price target of $207 per share implies that NBIX has another 45% in upside over the next 12 months.
Monolithic Power Systems
- Sector: Technology
- Market cap: $72.6 billion
- Long-term earnings growth estimate: 34%
- Consensus analyst rating: 1.35 (Strong Buy)
Semiconductor stocks will always feature prominently in any list of the best growth stocks, but Monolithic Power Systems (MPWR) isn't your average chip company.
MPWR designs, produces, and sells power circuits found in the automotive, enterprise data, consumer, communications, industrial, and other markets worldwide. These systems help convert and control voltages of a wide array of electronic systems, from servers, apps, and notebooks to home appliances and satellite communications. That's a big change from where Monolithic used to be.
"MPS is one of the best-positioned semiconductor names for upside this year," say Oppenheimer analysts, who rate the stock at Outperform. “A deep product pipeline and steady flow of design wins have steadily diversified MPWR away from traditional consumer products and into the communications, industrial, automotive, and networking markets. MPWR sets up well to outperform the broader semiconductor market with both an improving margin profile and an accelerating top-line outlook.”
Invest With CIBC
CIBC Investor's Edge lets you trade U.S. and Canadian stocks and ETFs, options, mutual funds, and bonds through registered accounts like FHSAs, TFSAs, RRSPs, and RESPs, as well as non-registered accounts.
Sign up with CIBC Investor's Edge today and enjoy commission-free trading on more than 180 ETFs.
Monolithic's boffo 2026 calmed down during the summer months, but it has recovered of late and is up by more than 55% year-to-date as I write this. You can thank a couple of solid quarterly earnings reports and a 28% hike to the dividend, to $2 per share quarterly.
"Monolithic Power reported another strong beat-and-raise quarter as AI infrastructure demand pulls through significant power silicon content," say William Blair's Sebastien Naji and Ana Bilbao, who rate the stock at Buy. "An even stronger third-quarter guide calls for higher growth in the back half of 2026 as new generation GPU and ASIC programs ramp up. MPS's continued technology leadership, strong alignment to AI spending, and diverse set of growth vectors position it well to maintain its track record of outperformance."
MPWR isn't as widely covered as bigger-name tech stocks, but it still enjoys a stellar consensus rating. Broken down by call, Monothlic Power Systems boasts 15 Buys versus just two Holds and no Sells.
Looking forward, analysts expect revenues to improve by around 45% annually over the next two years, and longer-term estimates peg profit growth at 34% per year on average.
Comfort Systems USA
- Sector: Industrials
- Market cap: $64.3 billion
- Long-term earnings growth estimate: 45%
- Consensus analyst rating: 1.20 (Strong Buy)
Comfort Systems USA (FIX) provides mechanical, electrical, and plumbing (MEP) contracting services. It offers heating, ventilation, and air conditioning (HVAC) systems, plumbing, electrical, modular construction, even fire protection. It installs, maintains, repairs, and replaces these systems in both new and existing buildings.
It's a cyclical business, but one that has been given a shot in the arm by a demand boom in data centers and other advanced manufacturing projects. Revenues quadrupled between 2020 and 2025. Net income has exploded by 580% in that time. And shares have reflected that wild growth, rocketing roughly 2,250% higher over the past five years.
Wall Street thinks the good times can keep rolling, too.
Related: 16 Best Stock Research + Analysis Apps, Tools and Software
"Comfort Systems is uniquely positioned to leverage capacity investments in data centers, manufacturing and other critical sectors, with significant customer planning occurring in core Comfort markets served," say Oppenheimer analysts, who rate the stock at Outperform. "Modular supplements opportunities in these core regions. These factors have supported (and likely will continue to support) superior growth and margin expansion potential vs. most industry peers over the near and medium term. We expect these factors, coupled with substantial excess liquidity in support of strategic initiatives, to lend varying upside levers to support a valuation premium to the industry peer group."
FIX doesn't have a huge analyst following, but nine of the 10 that cover the stock call it a Buy, with the lone dissenter a Hold. Meanwhile, an average price target of $2,197 implies an additional 28% of upside over the next year or so.
Also worth noting is that Comfort Systems' breakneck growth is also reflected in the company's dividend. The company offers a meager 0.2% headline yield, but that's largely an effect of its constantly rising share price. But the distribution has expanded from 10.5¢ per share quarterly in 2020 to 90¢ today, for a whopping expansion of 757%. That puts FIX in elite company of being both one of the market's top dividend-growth stocks and one of the best growth stocks period.
Related: 14 Best Investing Research & Stock Analysis Websites [2026]
Get Elite Stock Analysis From Seeking Alpha
Among our favorite platforms for both data and picks is Seeking Alpha Premium, which gives you unlimited access to thousands of active authors who deliver stock analysis.
Seeking Alpha also provides you with stock research tools, real-time news updates, crowdsourced debates, and market data. Users can create their own portfolio of favorite stocks, see how they perform, and receive email alerts or push notifications about their investments.
Try out Seeking Alpha Premium free for seven days and get a discount on your first year's subscription.
Read More From Young and the Invested
- Plynk Review: Great for All Investors, Easy on Beginners
- Empower Personal Strategy Review: Wealth Management More People Can Afford
- Morningstar Investor Review: Is This Research Tool Right for You?